-
Mashup Score: 2Impact of Alopecia Areata on Pediatric Patients and Their Families: Insights from a Single-Center Study in Turkey - 13 hour(s) ago
Alopecia areata (AA) is known to impact the health-related quality of life (HRQoL) of affected individuals, yet there is a paucity of research focusing on its effects specifically in pediatric patients and their families. To address this gap, researchers recently conducted a single-center cross-sectional cohort study aimed at assessing the HRQoL of pediatric patients diagnosed with AA and evaluating its impact on their parents. Between December 2020 and December 2021, researchers enrolled 72 pediatric patients with AA from the dermatology department of a tertiary center in Turkey. They used the Children’s Dermatology Life Quality Index (CDLQI) to gauge the HRQoL of pediatric patients, and the Dermatological Family Impact Scale (DeFIS) to evaluate the impact on their parents (often primary caregivers in the disease process). The results showed a mean CDLQI score of 8.4 ± 5.3 among the pediatric cohort, indicating moderate impairment. The symptoms and feelings domain exhibited the highes
Source: practicaldermatology.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 0Oral and Topical Minoxidil for Male Androgenetic Alopecia Show Similar Efficacy: Analysis - 4 day(s) ago
Low-dose oral minoxidil (5 mg once daily) was found to have similar effectiveness to topical minoxidil (5% twice per day) for the treatment of male androgenetic alopecia (AGA). The authors conducted the double-blind, placebo-controlled randomized clinical trial in Brazil aiming to evaluate the efficacy, safety, and tolerability of low-dose oral minoxidil compared to topical minoxidil in treating male AGA. The study included 90 men aged 18 to 55 years with AGA classified as 3V, 4V, or 5V on the Norwood-Hamilton scale. Participants were randomized into one group receiving daily oral minoxidil (5 mg) and topical placebo, and the other group receiving topical minoxidil (5%) twice daily and oral placebo. The study period was 24 weeks. Primary outcome measures included change in terminal hair density on the frontal and vertex regions of the scalp, with secondary outcomes including changes in total hair density and photographic evaluation. Of the 90 enrolled participants, 68 completed the st
Source: practicaldermatology.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 0
A single session of treatment with a fractional carbon dioxide laser followed by botulinum toxin type A was associated with significant reduction of facial pores in a pilot study presented at the American Society for Laser Medicine and Surgery (ASLMS) 43rd Annual Conference on Energy-based Medicine and Science in Baltimore. Enlarged facial pores are a common aesthetic concern, and fractional carbon dioxide (FxCO2) has shown success in minimizing pore size, but its use in combination with intradermal botulinum toxin type A (BTX-A) has not been examined, wrote Nattaporn Sampattavanich, MD, of Phramongkutklao Hospital, Bangkok, Thailand, and colleagues in an abstract presented at the annual conference of the American Society for Laser Medicine and Surgery. The researchers conducted a split-face pilot study of 15 adults with large facial pores. All participants underwent an initial session of FxCO2 applied to both cheeks, followed immediately by an injection of 16 units of BTX-A in one che
Source: practicaldermatology.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 0Top Non-cosmetic Laser Indications Vary by Laser Type - 8 day(s) ago
Treatment of psoriasis, vascular lesions, and hypertrophic disorders were the most common non-cosmetic indications for dermatologic use of excimer, vascular, and ablative lasers, respectively, based on data from more than 55,000 individuals. Non-cosmetic laser therapy in dermatology has experiencing significant growth in recent years, but the demographics and indications have not been examined, wrote Serena Yun-Chen Tsai, MD, of Harvard University, Boston, and colleagues in an abstract presented at the annual conference of the American Society for Laser Medicine and Surgery. In a population-based study, the researchers reviewed electronic health records for 56,784 adult patients who underwent non-cosmetic laser therapy (excimer, ablative, or vascular) at 92 healthcare organizations in the United States between January 2013 and December 2023. Overall, the mean age of the patients was 45.3 years, and half were female. Among the 42,898 patients underwent excimer laser therapy, psoriasis w
Source: practicaldermatology.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 0
In this episode of DermWire TV, a new analysis highlights factors affecting long-term antibiotic prescriptions for acne; a company developing plaque psoriasis biologics makes a major acquisition; and Practical Dermatology launches two new video series focusing on advancing treatment and improving understanding of atopic dermatitis. (AD), as well as a new series of C-Suite interviews.
Source: practicaldermatology.comCategories: General Medicine News, DermatologyTweet-
In this episode of DermWire TV, a new analysis highlights factors affecting long-term antibiotic prescriptions for acne; a company developing plaque psoriasis biologics makes a major acquisition; and Practical Dermatology launches two new video series: https://t.co/bZ2FDE3Lz4 https://t.co/RquoFFm2Tv
-
-
Mashup Score: 1
A recent analysis of the phase 1b KEYNOTE-041 trial indicated effectiveness and tolerability of pembrolizumab in Japanese patients with advanced melanoma. Researchers conducted the study over a 12-month period. The study evaluated pembrolizumab’s long-term efficacy and safety in individuals with locally advanced (unresectable stage III) or metastatic (stage IV) melanoma who were ineligible for local therapy. Patients had all received limited prior systemic treatments. The study drug was administered at a dosage of 2 mg/kg every 3 weeks for up to 2 years or until confirmed disease progression or intolerable side effects. According to the results, pembrolizumab exhibited a promising overall response rate (ORR) of 24.3% among evaluable patients, with two patients achieving complete response following initial partial response. Median overall survival (OS) reached 25.1 months, with a 30-month OS rate of 46.3%, indicating durable antitumor activity. Furthermore, the median duration of respon
Source: practicaldermatology.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 1
Deucravacitinib, a TYK-2 inhibitor, was linked with significant improvements in patient-reported outcomes (PROs) in patients with active psoriatic arthritis (PsA), according to results from a phase 2 trial. To assess the effects of deucravacitinib in this patient population, the study authors conducted a double-blind and randomized trial that included 203 patients with active PsA who were assigned to receive either deucravacitinib at doses of 6 mg or 12 mg once daily or a placebo over a period of 16 weeks. Key secondary endpoints included changes from baseline at Week 16 in the Health Assessment Questionnaire Disability Index (HAQ-DI) and the 36-item Short Form Health Survey (SF-36) physical component summary (PCS) score. Additional PROs (fatigue, pain, and mental health) were also assessed. The results showed that both doses of deucravacitinib led to significant improvements in HAQ-DI and SF-36 PCS scores compared to the placebo group. Moreover, a higher proportion of patients receivi
Source: practicaldermatology.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 0Study Validates Thermal Imaging, ALT-70 Model for Distinguishing Cellulitis from Pseudocellulitis - 19 day(s) ago
A new diagnostic validation study in JAMA Dermatology has shed light on the potential of surface thermal imaging and the ALT-70 (asymmetry, leukocytosis, tachycardia, and age ≥70 years) prediction model in differentiating cellulitis from pseudocellulitis. “Cellulitis is misdiagnosed in up to 30% of cases due to mimic conditions termed pseudocellulitis,” the authors wrote. “The resulting overuse of antibiotics is a threat to patient safety and public health. Surface thermal imaging and the ALT-70 (asymmetry, leukocytosis, tachycardia, and age ≥70 years) prediction model have been proposed as tools to help differentiate cellulitis from pseudocellulitis.” The authors conducted the study in patients presenting with acute dermatologic lower extremity symptoms in the ED, aiming to validate differences in skin surface temperatures between cellulitis and pseudocellulitis cases. They assessed various temperature measures and optimal cut points for differentiation, comparing their performance wi
Source: practicaldermatology.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 0Gene Variants May Drive Persistent Lesions in Darier Disease - 23 day(s) ago
Persistent lesions in patients with Darier disease were associated with second-hit variants in the ATP2A2 gene, according to data from a new case series of 9 patients. In a study published in JAMA Dermatology, Lihi Atzmony, MD, of Rabin Medical Center, Petach Tikva, Israel, and colleagues extracted DNA from areas of unaffected skin, transient lesional skin, persistent lesional skin, and blood from 9 adults with Darier disease (DD), a genetic skin disorder caused by heterozygous loss of function variants in the ATP2A2 gene and characterized by recurrent hyperkeratotic papules and plaques. These lesions may be mild or severe, and may be resistant to therapy. Additional somatic changes might impact the persistence of lesions in DD patients, the researchers wrote. Whole exome sequencing of ATP2A2 revealed germline and second-hit somatic variations of ATP2A2 in 6 of 6 patients with 8 persistent lesions. In addition, deep sequencing revealed two somatic variants in the persistent cutaneous l
Source: practicaldermatology.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 1Integrated Dermatology Appoints Tushar Ramani, MD, as CEO - 25 day(s) ago
Integrated Dermatology has announced the appointment of Tushar Ramani, MD, as the company’s new chief executive officer (CEO). Dr. Ramani will be replacing Jeff Queen, who after two decades as CEO and executive chairman, is transitioning to the role of co-executive chairman of the Board alongside Andy Queen. Dr. Ramani brings a combination of clinical expertise gained as a former anesthesiologist, along with entrepreneurial success as the founder and operator of several nationally prominent healthcare service companies. In his new role, Dr. Ramani’s strategic vision will include expanding the company’s dermatology partner network, implementing new technologies to enhance support services, and driving innovation while continuing to deliver high-quality dermatology care. With over 30 years of healthcare industry experience, including executive leadership roles at both publicly-traded and privately-held companies, Dr. Ramani most recently served as CEO of Women’s Care. “I am excited to j
Source: practicaldermatology.comCategories: General Medicine News, DermatologyTweet
Alopecia areata (AA) is known to impact the health-related quality of life (HRQoL) of affected individuals, yet there is a paucity of research focusing on its effects specifically in pediatric patients and their families. Read on here: https://t.co/37b1wJCaXj